FIELD: biotechnology.
SUBSTANCE: use of a pharmaceutical composition including as an active ingredient a genetic structure, which contains a nucleotide sequence encoding protein CCN5, and a pharmaceutically acceptable carrier is proposed for the prevention or treatment of cardiac arrhythmia. The use of a pharmaceutical composition including as an active ingredient an expression vector carrying a nucleotide sequence encoding protein CCN5 and a pharmaceutically acceptable carrier is proposed for the prevention or treatment of cardiac arrhythmia. The use of a pharmaceutical composition including as an active ingredient a recombinant virus, which contains a nucleotide sequence encoding protein CCN5, and a pharmaceutically acceptable carrier is proposed for the prevention or treatment of cardiac arrhythmia. The use of a pharmaceutical composition including protein CCN5 and a pharmaceutically acceptable carrier is proposed for the prevention or treatment of cardiac arrhythmia. The use of a pharmaceutical composition containing as an active ingredient a genetic structure, which contains a nucleotide sequence encoding protein CCN5, or an expression vector carrying a nucleotide sequence encoding protein CCN5, or a recombinant virus, which contains a nucleotide sequence encoding protein CCN5, and a pharmaceutically acceptable carrier is also proposed for the manufacture of a drug for the prevention or treatment of cardiac arrhythmia. A method for the prevention or treatment of cardiac arrhythmia is proposed, including the administration to a subject of protein CCN5, as well as a method for the prevention or treatment of cardiac arrhythmia, including the administration of a pharmaceutical composition containing as an active ingredient a genetic structure, which contains a nucleotide sequence encoding protein CCN5, or an expression vector carrying a nucleotide sequence encoding protein CCN5, or a recombinant virus, which contains a nucleotide sequence encoding protein CCN5, and a pharmaceutically acceptable carrier.
EFFECT: invention can be effectively used for the prevention or treatment of cardiac arrhythmia.
26 cl, 1 tbl, 2 ex, 77 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEART FAILURE | 2018 |
|
RU2788124C2 |
| METHODS FOR TREATMENT OF DANON'S DISEASE AND OTHER AUTOPHAGY DISORDERS | 2017 |
|
RU2777571C2 |
| OPTIMIZED GENES AND EXPRESSION CASSETTES OF MINI-DYSTROPHIN AND THEIR APPLICATION | 2017 |
|
RU2753194C2 |
| VARIANTS OF ACID ALPHA-GLUCOSIDASE AND THEIR USE | 2017 |
|
RU2780410C2 |
| RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2809246C2 |
| GENOTHERAPY CONSTRUCTIONS FOR TREATMENT OF WILSON'S DISEASE | 2020 |
|
RU2807158C2 |
| ISOLATED MODIFIED VPI CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED THEREON | 2021 |
|
RU2825667C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING MUCOLIPIDOSIS TYPE II | 2016 |
|
RU2742612C2 |
| CHIMERIC PROTEINS BASED ON HUMAN UTROPHIN AND DYSTROPHIN AND USE THEREOF FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | 2021 |
|
RU2767335C1 |
